Cardiol Res

Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access

Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc

Journal website https://www.cardiologyres.org

Original Article

Volume 6, Number 4-5, October 2015, pages 311-315

Influence of a Cardiac Rehabilitation Program on Renal Function in Patients With Cardiovascular Disease in a One-Year Follow-Up

Figure 1. Effects of CR on (A) UN, (B) Cr and (C) eGFR in blood in patients with low eGFR (closed circles) and high eGFR (open circles) in the CR group. (D) Effects of CR on eGFR in blood in patients with eGFR ≥ 70 (open squares) and < 70 mL/min/1.73 m² (closed squares) at baseline in the high eGFR group. *P < 0.05 vs. at baseline.

**Table 1.** Patient Characteristics at Baseline in the Non-CR and CR Groups
	Non-CR group(n = 26)	CR group (n = 23)
HTN: hypertension; DM: diabetes mellitus; DL: dyslipidemia; HF: heart failure; IHD: ischemic heart disease; ARB: angiotensin II receptor blocker; ACE-I: angiotensin converting enzyme inhibitor; CCB: calcium channel blocker. *P < 0.05 vs. non-CR group.
Age, years	69 ± 11	69 ± 10
Male, n (%)	15 (58)	19 (82)
HTN, n (%)	18 (70)	20 (87)
DM, n (%)	6 (23)	7 (30)
DL, n (%)	18 (70)	15 (65)
HF, n (%)	7 (27)	19 (83)*
IHD, n(%)	15 (58)	14 (61)
Medication
ARB/ACE-I, n (%)	14 (54)	13 (57)
Statin, n (%)	13 (50)	9 (39)
Diuretics, n (%)	6 (23)	11 (48)
CCB, n (%)	19 (73)	11 (48)*
β-blocker, n (%)	18 (69)	13 (57)

Table 1. Patient Characteristics at Baseline in the Non-CR and CR Groups

Non-CR group(n = 26)

CR group (n = 23)

HTN: hypertension; DM: diabetes mellitus; DL: dyslipidemia; HF: heart failure; IHD: ischemic heart disease; ARB: angiotensin II receptor blocker; ACE-I: angiotensin converting enzyme inhibitor; CCB: calcium channel blocker. *P < 0.05 vs. non-CR group.

Age, years

69 ± 11

69 ± 10

Male, n (%)

15 (58)

19 (82)

HTN, n (%)

18 (70)

20 (87)

DM, n (%)

6 (23)

7 (30)

DL, n (%)

18 (70)

15 (65)

HF, n (%)

7 (27)

19 (83)*

IHD, n(%)

15 (58)

14 (61)

Medication

ARB/ACE-I, n (%)

14 (54)

13 (57)

Statin, n (%)

13 (50)

9 (39)

Diuretics, n (%)

6 (23)

11 (48)

CCB, n (%)

19 (73)

11 (48)*

β-blocker, n (%)

18 (69)

13 (57)

**Table 2.** Biochemical Parameters in Blood at Baseline and at 1-Year in the Non-CR and CR Groups
	Non-CR group (n = 26)	CR group (n = 23)
UN: urea nitrogen; Cr: creatinine; eGFR: estimated glomerular filtration rate; K: potassium; Hct: hematocrit. *P < 0.05 vs. at baseline in the non-CR group.
BUN (mg/dL)	16 ± 4.4	16 ± 5.1	19 ± 6.2	18 ± 4.4
Cr (mg/dL)	0.9 ± 0.2	0.9 ± 0.1	1.1 ± 0.3*	1.1 ± 0.2
eGFR (mL/min)	60 ± 12	60 ± 12	54 ± 14	53 ± 11
K (mmol/L)	4.5 ± 0.6	4.4 ± 0.4	4.4 ± 0.5	4.4 ± 0.6
Hct (%)	42 ± 4.2	43 ± 4	37 ± 8.7*	40 ± 3.6

Table 2. Biochemical Parameters in Blood at Baseline and at 1-Year in the Non-CR and CR Groups

Non-CR group (n = 26)

CR group (n = 23)

Baseline

1 year

Baseline

1 year

UN: urea nitrogen; Cr: creatinine; eGFR: estimated glomerular filtration rate; K: potassium; Hct: hematocrit. *P < 0.05 vs. at baseline in the non-CR group.

BUN (mg/dL)

16 ± 4.4

16 ± 5.1

19 ± 6.2

18 ± 4.4

Cr (mg/dL)

0.9 ± 0.2

0.9 ± 0.1

1.1 ± 0.3*

1.1 ± 0.2

eGFR (mL/min)

60 ± 12

54 ± 14

53 ± 11

K (mmol/L)

4.5 ± 0.6

4.4 ± 0.4

4.4 ± 0.5

4.4 ± 0.6

Hct (%)

42 ± 4.2

43 ± 4

37 ± 8.7*

40 ± 3.6

**Table 3.** Patient Characteristics at Baseline in the High and Low eGFR Groups
	High eGFR group (n = 11)	Low eGFR group (n = 12)
HTN: hypertension; DM: diabetes mellitus; DL: dyslipidemia; HF: heart failure; IHD: ischemic heart disease; ARB: angiotensin II receptor blocker; ACE-I: angiotensin converting enzyme inhibitor; CCB: calcium channel blocker.
Age, years	67 ± 12	72 ± 9
Male, n (%)	8 (72)	10 (83)
HTN, n (%)	10 (91)	10 (83)
DM, n (%)	2 (18)	5 (42)
DL, n (%)	7 (64)	8 (67)
HF, n (%)	8 (72)	11 (92)
IHD, n (%)	8 (72)	6 (50)
Medication
ARB/ACE-I, n (%)	6 (55)	7 (58)
Statin, n (%)	6 (55)	3 (25)
Diuretics, n (%)	3 (27)	8 (67)
CCB, n (%)	4 (36)	7 (58)
β-blocker, n (%)	6 (55)	7 (58)

Table 3. Patient Characteristics at Baseline in the High and Low eGFR Groups

High eGFR group (n = 11)

Low eGFR group (n = 12)

Age, years

67 ± 12

72 ± 9

Male, n (%)

8 (72)

10 (83)

HTN, n (%)

10 (91)

10 (83)

DM, n (%)

2 (18)

5 (42)

DL, n (%)

7 (64)

8 (67)

HF, n (%)

8 (72)

11 (92)

IHD, n (%)

8 (72)

6 (50)

Medication

ARB/ACE-I, n (%)

6 (55)

7 (58)

Statin, n (%)

6 (55)

3 (25)

Diuretics, n (%)

3 (27)

8 (67)

CCB, n (%)

4 (36)

7 (58)

β-blocker, n (%)

6 (55)

7 (58)